UBS Group AG increased its holdings in Kestra Medical Technologies, Ltd. (NASDAQ:KMTS – Free Report) by 34.9% during the fourth quarter, HoldingsChannel.com reports. The fund owned 270,058 shares of the company’s stock after buying an additional 69,908 shares during the period. UBS Group AG’s holdings in Kestra Medical Technologies were worth $7,162,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors have also modified their holdings of the business. Farther Finance Advisors LLC acquired a new position in shares of Kestra Medical Technologies in the 4th quarter valued at $31,000. Millennium Management LLC increased its holdings in shares of Kestra Medical Technologies by 534.7% in the 3rd quarter. Millennium Management LLC now owns 219,706 shares of the company’s stock valued at $5,220,000 after acquiring an additional 185,090 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Kestra Medical Technologies in the 3rd quarter valued at $185,000. Bank of America Corp DE grew its position in Kestra Medical Technologies by 161.2% in the 3rd quarter. Bank of America Corp DE now owns 21,591 shares of the company’s stock valued at $513,000 after buying an additional 13,325 shares during the last quarter. Finally, Alliancebernstein L.P. grew its position in Kestra Medical Technologies by 13.7% in the 3rd quarter. Alliancebernstein L.P. now owns 1,491,970 shares of the company’s stock valued at $35,449,000 after buying an additional 179,885 shares during the last quarter.
Insider Transactions at Kestra Medical Technologies
In related news, insider Brian Daniel Webster sold 15,000 shares of the firm’s stock in a transaction on Friday, May 15th. The stock was sold at an average price of $20.96, for a total transaction of $314,400.00. Following the transaction, the insider directly owned 334,786 shares in the company, valued at $7,017,114.56. This trade represents a 4.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders sold 45,000 shares of company stock worth $919,050 in the last quarter. Company insiders own 3.60% of the company’s stock.
Wall Street Analysts Forecast Growth
Read Our Latest Report on Kestra Medical Technologies
Kestra Medical Technologies Stock Down 1.2%
KMTS opened at $19.59 on Tuesday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 7.32 and a current ratio of 7.32. Kestra Medical Technologies, Ltd. has a 1 year low of $13.25 and a 1 year high of $30.00. The firm has a 50 day moving average price of $20.65 and a 200 day moving average price of $23.86. The company has a market cap of $1.14 billion, a PE ratio of -4.95 and a beta of 0.82.
Kestra Medical Technologies (NASDAQ:KMTS – Get Free Report) last released its earnings results on Tuesday, March 17th. The company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.01). The business had revenue of $24.55 million for the quarter. Kestra Medical Technologies had a negative net margin of 171.87% and a negative return on equity of 65.49%. Kestra Medical Technologies’s revenue was up 62.7% compared to the same quarter last year. Sell-side analysts expect that Kestra Medical Technologies, Ltd. will post -2.34 earnings per share for the current year.
About Kestra Medical Technologies
We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.
Featured Stories
- Five stocks we like better than Kestra Medical Technologies
- Why Applied Optoelectronics Stock May Be Near a Turning Point
- From High-Yield to High-Growth: 3 Stocks Boosting Dividends
- Is Everspin Technologies the Next AI Edge Breakout?
- 5 Robotics Stocks to Watch as Physical AI Builds Momentum
Want to see what other hedge funds are holding KMTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kestra Medical Technologies, Ltd. (NASDAQ:KMTS – Free Report).
Receive News & Ratings for Kestra Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kestra Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
